Trial reportFrontiers in neurology2025
Red-light photobiomodulation improves cognition and neuropsychiatric symptoms in post-stroke cognitive impairment: a randomized trial.
Trial report in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Effects of Phototherapy on Sleep, Fatigue and Quality of Life in Dermatology Patients: A Pilot Study.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Application of photobiomodulation in post-stroke dysfunctions: a literature review of recent clinical studies.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute stroke patients often develop post-stroke cognitive impairment (PSCI) and dysthymic disorders. Formaldehyde (FA) induces cognitive decline and depression; while red light (RL) at 630 nm can degrade FA by activating FA-dehydrogenase (FDH). This study investigates the therapeutic effects of a novel RL device on cognitive function and neuropsychiatric symptoms in patients with PSCI. Methods: This was an exploratory, parallel-group, randomized controlled trial with concealed allocation, assessor blinding and intention-to-treat analysis. Stroke patients ( Results: The phototherapy device improved cognitive abilities, reduced anxiety and depression, lessened stroke severity, and enhanced daily living activities in the PSCI-RL group at 6 months. Additionally, RL therapy altered FA metabolism, as it lowered SSAO and H Conclusions: RL therapy may improve clinical symptoms in post-stroke patients by modulating FA metabolism, suggesting a safe and promising approach for treatment and rehabilitation. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=159956, Identifier: ChiCTR2200058991.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.